Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Dermata Therapeutics Inc WT
(NQ:
DRMAW
)
0.0096
UNCHANGED
Streaming Delayed Price
Updated: 1:31 PM EDT, May 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dermata Therapeutics Inc WT
< Previous
1
2
Next >
Dermata to Present at the Emerging Growth Conference on April 3, 2024
March 27, 2024
Via
ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on February 7, 2024
February 01, 2024
Via
ACCESSWIRE
Why Dermata Therapeutics Stock Took Off After-Hours
January 04, 2024
Dermata Therapeutics, Inc.
Via
Benzinga
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
January 04, 2024
Via
ACCESSWIRE
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
December 20, 2023
Via
ACCESSWIRE
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
November 16, 2023
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 10, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 24, 2023
Via
ACCESSWIRE
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
November 16, 2023
Via
ACCESSWIRE
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne
June 27, 2023
Via
ACCESSWIRE
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
June 13, 2023
Via
ACCESSWIRE
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
June 08, 2023
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
February 21, 2023
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 10, 2022
Via
ACCESSWIRE
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 26, 2023
Via
ACCESSWIRE
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
April 20, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
March 20, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering
March 16, 2023
Via
ACCESSWIRE
Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
December 05, 2022
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 15, 2022
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 16, 2022
Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc....
From
Dermata Therapeutics
Via
AccessWire
Exposures
Product Safety
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 25, 2022
SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of...
From
Dermata Therapeutics
Via
AccessWire
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 21, 2022
SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment...
From
Dermata Therapeutics
Via
AccessWire
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
March 28, 2022
DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023 DMT310 Phase...
From
Dermata Therapeutics
Via
AccessWire
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021
- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - -...
From
Dermata Therapeutics
Via
AccessWire
Topics
Initial Public Offering
Exposures
Product Safety
Securities Market
Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
September 21, 2021
The presentation will highlight efficacy and safety data from a Phase 1b proof of concept study evaluating one application of DMT410 as a new topical intradermal delivery mechanism of botulinum toxin...
From
Dermata Therapeutics
Via
AccessWire
Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
September 01, 2021
SAN DIEGO, CA / ACCESSWIRE / September 1, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biopharmaceutical company focused on the...
From
Dermata Therapeutics
Via
AccessWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.